APA (7th ed.) Citation

Reiter, A., Gotlib, J., Álvarez-Twose, I., Radia, D. H., Lübke, J., Bobbili, P. J., . . . DeAngelo, D. J. (2022). Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis: Myelodysplastic syndrome. Leukemia, 36(8), . https://doi.org/10.1038/s41375-022-01615-z

Chicago Style (17th ed.) Citation

Reiter, Andreas, et al. "Efficacy of Avapritinib Versus Best Available Therapy in the Treatment of Advanced Systemic Mastocytosis: Myelodysplastic Syndrome." Leukemia 36, no. 8 (2022). https://doi.org/10.1038/s41375-022-01615-z.

MLA (9th ed.) Citation

Reiter, Andreas, et al. "Efficacy of Avapritinib Versus Best Available Therapy in the Treatment of Advanced Systemic Mastocytosis: Myelodysplastic Syndrome." Leukemia, vol. 36, no. 8, 2022, https://doi.org/10.1038/s41375-022-01615-z.